Bill Text: HI HB2332 | 2014 | Regular Session | Amended

---

Bill Title: Uniform Controlled Substances Act; Federal Conformity

Spectrum: Partisan Bill (Democrat 1-0)

Status: (Introduced - Dead) 2014-02-25 - The committee(s) on JUD recommend(s) that the measure be deferred. [HB2332 Detail]

Download: Hawaii-2014-HB2332-Amended.html

---

HOUSE OF REPRESENTATIVES	H.B. NO.	2332
TWENTY-SEVENTH LEGISLATURE, 2014		H.D. 1
STATE OF HAWAII

A BILL FOR AN ACT

 

 

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

 

 

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

 

     SECTION 1.  Section 329-14, Hawaii Revised Statutes, is amended as follows:

     1.  By amending subsection (d) to read:

     "(d)  Any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

     (1)  Alpha-ethyltryptamine (AET);

     (2)  2,5-dimethoxy-4-ethylamphetamine (DOET);

     (3)  2,5-dimethoxyamphetamine (2,5-DMA);

     (4)  3,4-methylenedioxy amphetamine;

     (5)  3,4-methylenedioxymethamphetamine (MDMA);

     (6)  N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-MDA);

     (7)  3,4-methylenedioxy-N-ethylamphetamine (MDE);

     (8)  5-methoxy-3,4-methylenedioxy-amphetamine;

     (9)  4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA);

    (10)  4-Bromo-2,5-dimethoxyphenethylamine (Nexus);

    (11)  3,4,5-trimethoxy amphetamine;

    (12)  Bufotenine;

    (13)  4-methoxyamphetamine (PMA);

    (14)  Diethyltryptamine;

    (15)  Dimethyltryptamine;

    (16)  4-methyl-2,5-dimethoxy-amphetamine;

    (17)  Gamma hydroxybutyrate (GHB) (some other names include gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);

    (18)  Ibogaine;

    (19)  Lysergic acid diethylamide;

    (20)  Marijuana;

    (21)  Parahexyl;

    (22)  Mescaline;

    (23)  Peyote;

    (24)  N-ethyl-3-piperidyl benzilate;

    (25)  N-methyl-3-piperidyl benzilate;

    (26)  Psilocybin;

    (27)  Psilocyn;

    (28)  1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);

    (29)  Ethylamine analog of phencyclidine (PCE);

    (30)  Pyrrolidine analog of phencyclidine (PCPy, PHP);

    (31)  Thiophene analog of phencyclidine (TPCP; TCP);

    (32)  Gamma-butyrolactone, including butyrolactone; butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone; 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-hydroxybutyric acid lactone; 3-hydroxybutyric acid lactone and 4-hydroxybutanoic acid lactone with Chemical Abstract Service number 96-48-0 when any such substance is intended for human ingestion;

    (33)  1,4 butanediol, including butanediol; butane-1,4-diol;  1,4- butylenes glycol; butylene glycol; 1,4-dihydroxybutane; 1,4- tetramethylene glycol; tetramethylene glycol; tetramethylene 1,4- diol with Chemical Abstract Service number 110-63-4 when any such substance is intended for human ingestion;

    (34)  2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers;

    (35)  N-benzylpiperazine (BZP; 1-benzylpiperazine) its optical isomers, salts, and salts of isomers;

    (36)  1-(3-trifluoromethylphenyl)piperazine (TFMPP), its optical isomers, salts, and salts of isomers;

    (37)  Alpha-methyltryptamine (AMT), its isomers, salts, and salts of isomers;

    (38)  5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its isomers, salts, and salts of isomers;

    (39)  Salvia divinorum;

    (40)  Salvinorin A;

    (41)  Divinorin A; [and]

    (42)  5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DIPT) (some trade or other names: 5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT0[.];

    (43)  2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);

    (44)  2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);

    (45)  2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);

    (46)  2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);

    (47)  2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);

    (48)  2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);

    (49)  2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);

    (50)  2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);

    (51)  2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);

    (52)  2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5);

    (53)  2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); and

    (54)  2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36)."

     2.  By amending subsection (g) to read:

     "(g)  Any of the following cannabinoids, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:

     (1)  Tetrahydrocannabinols; meaning tetrahydrocannabinols naturally contained in a plant of the genus Cannabis (cannabis plant), as well as synthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, sp. or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant, such as the following: Delta 1 cis or trans tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans tetrahydrocannabinol, and their optical isomers; and Delta 3,4 cis or trans-tetrahydrocannabinol, and its optical isomers (since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions, are covered);

     (2)  Naphthoylindoles; meaning any compound containing a 3-(1-naphthoyl) indole structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;

     (3)  Naphthylmethylindoles; meaning any compound containing a 1H-indol-3-yl-(1-naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;

     (4)  Naphthoylpyrroles; meaning any compound containing a 3-(1-naphthoyl) pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent;

     (5)  Naphthylmethylindenes; meaning any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent;

     (6)  Phenylacetylindoles; meaning any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent;

     (7)  Cyclohexylphenols; meaning any compound containing a 2-(3-hydroxycyclohexyl) phenol structure with substitution at the 5-position of the phenolic ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not substituted in the cyclohexyl ring to any extent;

     (8)  Benzoylindoles; meaning any compound containing a 3-

(benzoyl) indole structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;

     (9)  2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone (another trade name is WIN 55,212-2);

    (10)  (6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-

methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (other trade names are: HU-210 and HU-211); [and]

    (11)  Tetramethylcyclopropanoylindoles; meaning any compound containing a 3-tetramethylcyclopropanoylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the tetramethylcyclopropyl ring to any extent[.]; and

    (12)  N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers. (Other names: APINACA, AKB48)."

     SECTION 2.  Section 329-18, Hawaii Revised Statutes, is amended by amending subsection (c) to read as follows:

     "(c)  Depressants.  Unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances having a depressant effect on the central nervous system:

     (1)  Any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital, or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule;

     (2)  Any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository;

     (3)  Any substance that contains any quantity of a derivative of barbituric acid or any salt thereof, including the substance butalbital;

     (4)  Chlorhexadol;

     (5)  Embutramide (Tributame);

     (6)  Ketamine, its salts, isomers, and salts of isomers, also known as (+ or -)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;

     (7)  Lysergic acid;

     (8)  Lysergic acid amide;

     (9)  Methyprylon;

    (10)  Sulfondiethylmethane;

    (11)  Sulfonethylmethane;

    (12)  Sulfonmethane;

    (13)  Tiletamine/Zolazepam (Telazol, 2-(ethylamino)-2-(-thienyl)-cyclohexanone, flupyrazapon) or any salts thereof; [and]

    (14)  Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers that are contained in a drug product for which an application has been approved under section 505 of the federal Food, Drug, and Cosmetic Act[.]; and

    (15)  Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile], including its salts, isomers, and salts of isomers."

     SECTION 3.  Section 329-20, Hawaii Revised Statutes, is amended by amending subsection (d) to read as follows:

     "(d)  Stimulants.  Unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

     (1)  Cathine ((+)-norpseudoephedrine);

     (2)  Diethylpropion;

     (3)  Fencamfamin;

     (4)  Fenproporex;

     (5)  Mazindol;

     (6)  Mefenorex;

     (7)  Modafinil;

     (8)  Phentermine;

     (9)  Pemoline (including organometallic complexes and chelates thereof);

    (10)  Pipradrol;

    (11)  Sibutramine; [and]

    (12)  SPA (1-dimethylamino-1,2-diphenylethane, lefetamine)[.]; and

    (13)  Lorcaserin."

     SECTION 4.  Statutory material to be repealed is bracketed and stricken.  New statutory material is underscored.

     SECTION 5.  This Act shall take effect upon its approval.

 

 

Report Title:

Uniform Controlled Substances Act; Federal Conformity

 

Description:

Updates the Uniform Controlled Substances Act to make it consistent with amendments to federal law on controlled substances by adding newly federally scheduled drugs to the lists for schedules I, III, and IV.  (HB2332 HD1)

 

 

 

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.